Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.46 |
| ▸ | PDE2A | O00408 | 8/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625024 | 0.91 | GRM4 (0.54) | HDAC1GRM4PDE2ANR3C1CTNNB1 | |
| SCHEMBL626126 | 0.87 | HSD17B14 (0.43) | HDAC1GRM4NR3C1HDAC3HDAC2 | |
| SCHEMBL14893822 | 0.82 | TLR7 (0.40) | GRM4CTNNB1WNT3A | |
| SCHEMBL15011536 | 0.82 | TLR7 (0.51) | GRM4PDE2ANR3C1 | |
| SCHEMBL624174 | 0.81 | TLR7 (0.50) | HDAC1NR3C1HDAC3HDAC2HDAC6 | |
| SCHEMBL624708 | 0.81 | TLR7 (0.44) | GRM4PDE2ACTNNB1WNT3A | |
| SCHEMBL624803 | 0.80 | HDAC4 (0.53) | HDAC1GRM4HDAC3HDAC2HDAC6 | |
| SCHEMBL625186 | 0.80 | P2RX7 (0.46) | NR3C1 | |
| SCHEMBL15011470 | 0.79 | P2RX7 (0.50) | HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL625121 | 0.79 | TLR7 (0.41) | GRM4PDE2ANR3C1CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | HDAC1 995/4885GRM4 242/4885PDE2A 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.